NASH is one of the leading causes of chronic liver disease with the potential of evolving
towards end-stage liver disease and HCC, even in the absence of cirrhosis. Apart from …

Intermittent fasting is a non-pharmacological dietary approach to management of obesity
and metabolic syndrome, involving periodic intervals of complete or near-complete …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic
disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has …

Background: Weight loss by lifestyle modification is the cornerstone therapy of non-alcoholic
fatty liver disease. Intermittent fasting has shown favorable effects on body weight and …

Non-alcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver injury,
affecting around one-fourth of the general population across the world. Several important …

Background Non-alcoholic fatty liver disease (NAFLD) is a predominant health condition
across the world due to its rising prevalence and association with various metabolic …

Objectives Intermittent fasting (IF) regimens have been hypothesized to influence several
markers of cardiometabolic and liver function. The objective of our meta-analysis was to …

Non-alcoholic fatty liver disease (NAFLD) represents a major public health concern and is
associated with a substantial global burden of liver-related and cardiovascular-related …

The role and molecular mechanisms of intermittent fasting (IF) in non-alcoholic
steatohepatitis (NASH) and its transition to hepatocellular carcinoma (HCC) are unknown …

Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic that encompasses three
distinct clinical phenotypes: uncomplicated fatty liver, nonalcoholic steatohepatitis (NASH) …